Table 2. Response of Poor-Risk AML... | American Society of Hematology

Table 2.

Response of Poor-Risk AML Patients to Induction Therapy With PSC-MEC

Patients	CR (%)	PR	Failed
Cohort I^* n = 6	1 (17%)	1	4
Cohort II^† n = 31	11 (35%)	3	17

Total n = 37	12 (32%)	4	21

Patients	CR (%)	PR	Failed
Cohort I^* n = 6	1 (17%)	1	4
Cohort II^† n = 31	11 (35%)	3	17

Total n = 37	12 (32%)	4	21

Cohort I patients were treated with mitoxantrone 5 mg/m²/d, etoposide 50 mg/m²/d, Ara-C 1 g/m²/d plus PSC for 5 days.

†

Cohort II patients received 20% lower doses of mitoxantrone (4 mg/m²/d) and etoposide (40 mg/m²/d), with similar cytarabine and PSC doses as for cohort I for 5 days.

View Large

This Feature Is Available To Subscribers Only